Akebia Therapeutics, Inc. (AKBA) Latest Broker Coverage
A number of investment brokers have recently updated their price targets on shares of Akebia Therapeutics, Inc. (AKBA). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
03/16/2016 – Akebia Therapeutics, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 14 price target on the stock.
03/15/2016 – Akebia Therapeutics, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 18 price target on the stock.
01/21/2016 – Credit Suisse began new coverage on Akebia Therapeutics, Inc. giving the company a “neutral” rating. They now have a USD 10 price target on the stock.
12/15/2015 – Akebia Therapeutics, Inc. had its “buy” rating reiterated by analysts at Brean Capital.
09/09/2015 – Akebia Therapeutics, Inc. was upgraded to “overweight” by analysts at Morgan Stanley. They now have a USD 17 price target on the stock.
06/22/2015 – JMP Securities began new coverage on Akebia Therapeutics, Inc. giving the company a “outperform” rating. They now have a USD 24 price target on the stock.
05/12/2015 – Akebia Therapeutics, Inc. had its “buy” rating reiterated by analysts at Nomura. They now have a USD 27 price target on the stock.
04/23/2014 – Zacks began new coverage on Akebia Therapeutics, Inc. giving the company a “hold” rating.
The share price of Akebia Therapeutics, Inc. (AKBA) was down -7.52% during the last day of trading, with a day high of 8.89. 831582 shares were traded during the last session.
The stock’s 50 day moving average is 9.30 and its 200 day moving average is 9.15. The stock’s market capitalization is 152.99M. Akebia Therapeutics, Inc. has a 52-week low of 5.91 and a 52-week high of 14.20.
View other investors thoughts on Akebia Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.